BridgeBio (BBIO) Wells Fargo 21st Annual Healthcare Conference summary

Business overview and growth outlook

• Post-phase III pipeline includes drugs for ADH1, limb-girdle, ATTR-CM, and achondroplasia, with $8B de-risked peak year sales potential and $10B risk-adjusted sales potential overall.

• Attruby's Q2 global revenues annualize over $1B, with U.S. revenues at $222M and consistent $25M-$30M quarter-over-quarter growth expected to continue.

• Launches of three new drugs in 2027 are anticipated to drive significant growth, with further acceleration expected as clinical messages gain traction.

• Innovation and unmet need in genetic diseases remain high, guiding future investment of generated cash flows.

ATTR-CM market dynamics and Attruby differentiation

• Stabilizers remain the frontline therapy for ATTR-CM, with over 80% of new patients starting on them, a trend reinforced by recent CARDIO-TTRansform data.

• Attruby is positioned as a next-generation stabilizer, expected to gain share from VYNDAMAX due to superior efficacy and unique nephroprotective effects.

• Real-world evidence, including independent studies, supports Attruby's benefits over tafamidis, with more data expected at upcoming conferences.

• Channel dynamics and specialty pharmacy control are expected to sustain Attruby's volume even after VYNDAMAX goes generic in 2031.

• The frontline market is expanding, with new patient starts doubling over two years, and Attruby's share now above 25% and growing.

Pipeline launches: limb-girdle, ADH1, and achondroplasia

• BBP-418 for limb-girdle muscular dystrophy type 2I/R9 showed statistically significant improvements from baseline in phase III, addressing a high unmet need in a 7,000-patient population across the U.S. and EU.

• Launch strategy for limb-girdle is capital efficient, targeting 150-160 MDA centers, with strong payer receptivity and anticipated premium pricing.

• Most limb-girdle patients are expected to be candidates for therapy, with rapid adoption driven by advocacy and early functional benefits.

• Encaleret for ADH1 targets a 12,000-patient prevalence, with concentrated endocrinology call points and potential for family-based diagnosis expansion.

• Encaleret pricing is expected between $300K-$500K, with a major expansion opportunity in hypoparathyroidism, supported by promising phase II data and expert enthusiasm.

• Infigratinib for achondroplasia demonstrated best-in-class efficacy, including benefits beyond height such as proportionality and reduced sleep apnea and ear infections.

• Infigratinib aims to capture patients switching from or avoiding injectable therapies, with potential to grow the market by appealing to new and previously untreated segments.